AtriCure (ATRC) Common Equity (2010 - 2026)

AtriCure (ATRC) has 17 years of Common Equity data on file, last reported at $491.7 million in Q1 2026.

• On a quarterly basis, Common Equity rose 8.15% year-over-year to $491.7 million in Q1 2026; TTM through Mar 2026 was $491.7 million, a 8.15% increase from a year earlier, with the FY2025 full-year figure at $491.9 million, up 6.72% from the prior year.
• Common Equity for Q1 2026 stood at $491.7 million, roughly flat from $491.9 million in the prior quarter.
• Over the last five years, Common Equity for ATRC reached as high as $491.9 million in Q4 2025 and fell as low as $450.3 million in Q3 2022.
• Historically, Common Equity has averaged $464.5 million across 5 years, with a median of $462.4 million in 2023.
• On a YoY basis, Common Equity climbed as much as 18.6% in 2022 and fell as far as 7.81% in 2022.
• Year by year, Common Equity stood at $456.8 million in 2022, then climbed by 2.06% to $466.2 million in 2023, then declined by 1.12% to $461.0 million in 2024, then grew by 6.72% to $491.9 million in 2025, then dropped by 0.05% to $491.7 million in 2026.
• Per Business Quant data, the three most recent Common Equity figures were $491.7 million in Q1 2026, $491.9 million in Q4 2025, and $476.5 million in Q3 2025.